奥马珠单抗可改善重度哮喘患者的一秒用力呼气容积。
Omalizumab improves forced expiratory volume in 1 second in patients with severe asthma.
作者信息
Pałgan Krzysztof, Żbikowska-Götz Magdalena, Lis Kinga, Chrzaniecka Elżbieta, Bartuzi Zbigniew
机构信息
Department of Allergy, Clinical Immunology and Internal Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland.
出版信息
Postepy Dermatol Alergol. 2018 Oct;35(5):495-497. doi: 10.5114/ada.2018.77241. Epub 2018 Jul 19.
INTRODUCTION
Asthma is a multiphenotypic disease, and therapeutic managenment in patients with severe asthma is particulary difficult, with conventional treatment of severe asthma showing poor efficacy.
AIM
To analyse forced expiratory volume in 1 s (FEV) following the adminstration of omalizumab.
MATERIAL AND METHODS
Six patinents (mean age: 50 ±12.6) with severe, uncontrolled asthma according to the GINA guidelines were enrolled in the study.
RESULTS
Treatment with omalizumab increased in all subjects FEV by 17.28 ±13.4% after months and 18.57 ±13.4% after 12 months of treatment.
CONCLUSIONS
These results provides further evidence that therapy with omalizumab improves spiromtric parameters in severe asthma.
引言
哮喘是一种多表型疾病，重度哮喘患者的治疗管理尤其困难，重度哮喘的传统治疗效果不佳。
目的
分析使用奥马珠单抗后1秒用力呼气容积（FEV）。
材料与方法
根据全球哮喘防治创议（GINA）指南，纳入6例重度、未控制哮喘患者（平均年龄：50±12.6岁）进行研究。
结果
所有受试者使用奥马珠单抗治疗数月后FEV增加17.28±13.4%，治疗12个月后增加18.57±13.4%。
结论
这些结果进一步证明，奥马珠单抗治疗可改善重度哮喘患者的肺功能参数。
Zotero 插件